Biosimilar Enbrel filed with EMA
This article was originally published in Scrip
Executive Summary
The next biosimilar to reach the EU market could well be a version of Amgen's TNF inhibitor Enbrel, after the European Medicines Agency revealed in a January update that its scientific committee, the CHMP, has a biosimilar etanercept under evaluation.